novel
coronaviru
viru
identifi
caus
outbreak
pneumonia
first
detect
wuhan
china
investig
transmiss
sever
featur
associ
viru
ongo
current
vaccin
therapeut
antibodi
prevent
infect
time
requir
develop
effect
immun
strategi
pathogen
contrast
specif
inhibitor
target
key
proteas
involv
replic
prolifer
viru
effect
mean
allevi
epidem
main
proteas
sarscov
essenti
life
cycl
viru
show
similar
main
proteaseof
consid
attract
target
drug
develop
studi
identifi
small
molecular
drug
high
bind
capac
sarscov
main
proteas
highthroughput
screen
base
clinic
drug
librari
drug
wide
use
clinic
applic
guarante
safeti
may
serv
promis
candid
treat
infect
sinc
decemb
seri
pneumonia
case
unknown
caus
emerg
wuhan
china
genom
sequenc
sampl
patient
confirm
culprit
infect
betacoronaviru
never
report
later
name
jan
patient
confirm
infect
nearli
patient
die
infect
far
infect
keep
spread
export
case
confirm
provinc
china
sever
countri
includ
unit
state
pose
great
pressur
public
health
secur
discoveri
clinic
applic
specif
drug
effect
mean
allevi
current
epidem
howev
clinic
effect
drug
viru
moment
although
significantli
differ
sarscov
breakout
beij
year
sequenc
ident
themi
high
sequenc
align
reveal
similar
sequenc
main
proteas
sarscov
previou
studi
demonstr
main
proteas
sarscov
essenti
life
cycl
viru
consid
attract
target
drug
develop
thu
protein
could
use
homolog
target
screen
drug
inhibit
replic
prolifer
order
screen
possibl
drug
candid
abl
prevent
cure
infect
highthroughput
screen
perform
base
clinic
drug
librari
use
onlin
softwar
vina
seesar
combin
inhous
automat
process
script
screen
program
small
molecular
drug
high
bind
capac
sarscov
main
proteas
identifi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
drug
wide
use
clinic
practic
safeti
guarante
view
activ
safeti
wildli
use
drug
feasibl
conduct
clinic
exploratori
treatment
special
case
outbreak
report
identifi
structur
molecul
cd
protein
wuhan
seafood
market
pneumonia
viru
access
obtain
nbci
databas
structur
sequenc
sarscov
main
proteas
download
pdb
databas
nearli
molecul
obtain
drugbank
includ
approv
experiment
compound
small
molecul
molecular
similar
search
perform
use
strategi
base
similar
sequenc
ofth
structurerev
molecul
ncbiblast
instal
local
machin
local
databas
establish
molecular
sequenc
sarscov
main
proteas
pdb
blastp
ran
default
paramet
autodock
vina
obtain
websit
scrippsedu
crystal
structur
main
proteas
monom
pdb
id
use
target
protein
remov
unrel
complex
molecul
autodocktool
receptor
prepar
remov
water
ad
hydrogen
comput
charg
bind
coordin
locat
grid
box
includ
cave
near
ntermin
joint
groov
dimer
autodock
perform
use
multithread
task
inhous
script
potenti
molecul
screen
perl
program
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
develop
us
candid
harvest
dock
deepli
analyz
atombas
affin
contribut
physicalchem
properti
seesar
version
biosolveit
gmbh
sankt
augustin
germani
wwwbiosolveitdeseesar
molecul
imag
display
pymol
affin
vina
less
kcalmol
harvest
initi
molecul
remov
toxin
experiment
unapprov
one
strong
side
effect
final
candid
drug
select
better
affin
vina
seesar
download
sequenc
total
sarscov
main
proteas
differ
origin
pdb
built
local
librari
homolog
align
result
reveal
similar
region
aa
ab
protein
sarscov
main
proteas
fig
thu
main
proteas
highli
conserv
main
proteas
use
homolog
target
screen
possibl
drug
three
bind
pocket
detect
viral
main
proteas
comput
label
comparison
dimer
monom
structur
protein
b
could
figur
pocket
bind
site
natur
substrat
pocket
joint
groov
two
monom
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
small
pocket
locat
c
termin
first
harvest
molecul
possibl
bind
capac
sarscov
main
proteas
dye
toxin
antitumor
drug
strong
side
effect
molecul
left
exclud
molecul
neurolog
drug
select
market
drug
kinet
biochem
analysi
final
molecul
identifi
bind
energi
molecul
prulifloxacin
fig
viral
main
proteas
kcalmol
kcalmol
kcalmol
three
bind
site
respect
fig
cave
adjac
ntermin
dimer
joint
groov
back
side
moreov
sever
dock
pose
estim
affinitiesof
bind
mm
evalu
ligandlipophil
effici
lle
torsion
clash
also
satisfi
bind
site
bictegravir
main
proteas
display
fig
bind
energi
bictegravir
major
proteas
kcalmol
joint
groov
kcalmol
activ
site
estim
affin
satisfi
fig
result
show
bind
site
nelfinavir
main
proteas
locat
joint
groov
fig
bind
energi
nelfinavir
major
proteas
kcalmol
estim
affin
seem
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
high
enough
fig
tegobuvir
dock
joint
groov
main
protein
bind
energi
kcalmol
estim
affin
satisfi
fig
bind
site
display
fig
although
coronavirus
extens
mutagenesi
key
protein
especi
replicationrel
enzym
highli
conserv
mutat
key
protein
often
lethal
viru
drug
target
conserv
proteas
usual
capabl
prevent
replic
prolifer
viru
exhibit
broad
spectrum
besid
reduc
risk
mutat
mediat
drugresist
current
studi
base
result
bioinformat
analysi
structur
sarscov
protein
select
homolog
target
molecul
screen
silico
high
throughput
screen
strategi
automat
pipelin
establish
use
classic
dock
softwar
inhous
program
greatli
acceler
screen
process
among
four
molecul
identifi
studi
prulifloxacin
chemotherapeut
fluoroquinolon
antibiot
broadspectrum
activ
approv
treatment
uncompl
complic
urinari
tract
infect
communityacquir
respiratori
tract
infect
itali
gastroenter
includ
infecti
diarrhea
japan
unfortun
prulifloxacin
report
prodrug
rapidli
metabol
ulifloxacin
vivo
use
lead
compound
provid
guidanc
later
structur
modif
optim
design
effect
main
proteas
inhibitor
tegobuvir
novel
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
nonnucleosid
inhibitor
nni
hcv
rna
replic
demonstr
antivir
activ
patient
genotyp
chronic
hcv
infect
addit
nelfinavir
bictegravir
antihiv
drug
nelfinavir
proteas
inhibitor
inhibit
cleavag
polyprotein
gagpol
wherea
bictegravir
new
potent
integras
inhibitor
abl
effici
prevent
hiv
multipli
reduc
amount
hiv
bodi
result
clearli
show
four
molecul
show
reason
bind
conform
viral
main
proteas
among
prulifloxacin
exhibit
three
bind
site
main
proteas
two
nelfinavir
bictegravir
molecul
prulifloxacin
tegobuvir
bictegravir
prefer
nelfinavira
confirm
affin
physicalchem
properti
analysi
use
seesar
base
pocket
function
target
protein
suggest
molecul
possess
abil
block
activ
site
interrupt
dimer
format
viral
protein
therefor
may
sever
promis
candid
drug
repurpos
develop
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
